Oral Ketamine Side Effects: What New TRD Data Tells Us

What the New Clinical Guidance Says

A 2026 analysis published in Psychiatric Times is pushing the psychiatry field toward faster, more data-driven treatment decisions for patients with treatment-resistant depression (TRD). The piece zeroes in on NMDA receptor antagonists — the drug class that includes both IV ketamine and oral ketamine formulations — and calls on clinicians to optimize doses sooner, switch medications when progress stalls, and track outcomes using structured tools like the PHQ-9 rather than waiting passively for remission to emerge.

The clinical message is pointed: too many TRD patients are spending too long on subtherapeutic doses or enduring side effects without a structured plan to reassess. The authors argue that understanding side effect profiles and discontinuation patterns isn't just academic — it directly shapes whether patients stick with treatment long enough to benefit.

For anyone taking ketamine in tablet form, or considering it, this guidance is directly relevant. Here's how to read it through the lens of oral ketamine.

Side Effect Profiles: How Oral Tablets Compare

NMDA antagonists as a class share a recognizable side effect signature: dissociation, dizziness, nausea, elevated blood pressure, and transient perceptual changes. But delivery route makes a dramatic difference in how intensely — and how quickly — those effects are felt.

IV infusions deliver ketamine directly into the bloodstream, producing peak plasma concentrations rapidly. This means the dissociative window is compressed and intense, typically 40–60 minutes, but resolves relatively quickly once the infusion ends. Blood pressure spikes are more pronounced and require clinical monitoring on-site.

Sublingual troches (lozenges dissolved under the tongue) sit in the middle of the absorption spectrum. Onset is faster than swallowed tablets because some drug is absorbed through the oral mucosa, but bioavailability varies significantly depending on how long the lozenge is held and individual mucosal absorption rates.

Oral tablets, by contrast, pass through the gastrointestinal tract, where ketamine undergoes substantial first-pass metabolism in the liver. The result is a slower, lower-peak plasma concentration compared to IV or even sublingual routes. This pharmacokinetic profile is clinically meaningful: dissociative side effects tend to be milder and more gradual in onset with oral tablets, which many patients — especially those who find the IV dissociative experience overwhelming — report as preferable. Nausea is the most commonly reported complaint with oral ketamine, partly because of GI transit itself and partly due to ketamine's emetic properties at higher concentrations.

Discontinuation rates in the broader NMDA antagonist literature are often driven by two factors: intolerable acute side effects and perceived lack of efficacy. Oral tablet users are somewhat insulated from the former due to the blunted peak effect, but this same characteristic — lower bioavailability — means adequate dosing is critical. Underdosing is a real risk with oral formulations, and patients who don't feel any effect may discontinue prematurely before a therapeutic dose is established.

What Faster Dose Optimization Means in Practice

The Psychiatric Times piece specifically calls out dose optimization and earlier switching as levers clinicians underuse. For oral ketamine patients, this translates to a few concrete considerations:

• Absorption variability matters. Oral ketamine bioavailability is affected by food intake, stomach acid levels, and individual metabolic differences. Taking tablets consistently — same time of day, same relationship to meals — reduces variability and makes it easier for your provider to evaluate whether the dose is actually working or just inconsistently absorbed.
• Side effect journaling has clinical value. The guidance emphasizes tracking both symptoms and side effects over time. Keeping a brief log of when side effects peak (and whether they're diminishing with repeated doses, as tolerance to dissociation often develops) helps distinguish a side effect pattern that will normalize from one that signals a real problem.
• Switching isn't failure. The analysis normalizes earlier switching among NMDA antagonists and between delivery formats when a patient isn't responding. If oral tablets are not delivering adequate benefit after a proper trial at an optimized dose, esketamine nasal spray (Spravato) or IV ketamine may be worth discussing. Each route has different access logistics, cost profiles, and monitoring requirements — but the data increasingly supports viewing the format as a variable to adjust, not a fixed commitment.
• Blood pressure monitoring remains relevant. Even at oral doses, ketamine can transiently elevate blood pressure. Patients with hypertension or cardiovascular risk factors should ensure their provider is aware and that periodic blood pressure checks are part of their monitoring plan, even outside a clinical setting.

The Bottom Line for Oral Ketamine Users

The 2026 clinical push for faster, data-driven TRD care is good news for patients — it means the standard of care is moving away from passive waiting and toward active, responsive management. For those using ketamine tablets specifically, the takeaway is practical: the oral route's gentler side effect profile is an advantage, but it comes with a responsibility to ensure dosing is adequate and to communicate early if something isn't working.

Side effects that are mild and transient with oral tablets are generally manageable with timing adjustments, anti-nausea measures, or minor dose changes. Persistent or severe effects warrant a direct conversation with your prescriber. And if you're tracking your own depression symptoms between appointments — which the evidence strongly supports — share that data. The faster your provider can see what's happening, the faster they can act.

Read the original clinical analysis at Psychiatric Times.